Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Frontline Bioventures Closes Second China RMB Life Science Fund

publication date: Mar 8, 2017
Frontline Bioventures, a China focused life science investor, has closed its second RMB fund, according to media reports. Frontline has not disclosed the amount of funds raised, as seems to be its habit, but Founder and Managing Partner Leon Chen did tell BioCentury the firm's second RMB fund was twice as big as its first (also not disclosed). Further, he said the firm now has $435 million under management, including the two RMB funds and a US dollar fund. Frontline, headquartered in Shanghai, also has offices in Hong Kong, Suzhou and San Francisco. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital